Why Chronic Hepatitis B Still Defies a Functional Cure: New Review Maps the Immunological Barriers

Chronic hepatitis B remains one of the most stubborn challenges in modern virology, and a comprehensive review published in Virology Journal by researchers at the Second Affiliated Hospital of Nanchang University has now brought together the molecular and immunological threads that explain why so few patients ever reach a functional cure. Writing in the open-access literature, virologists Lesheng Lin, Dongshan Yu and Shuilin Sun argue that the therapeutic goal for chronic hepatitis B (CHB) is not necessarily the complete eradication of the virus but the induction of a durable, treatment-free state of viral control — a state commonly described as a functional cure. In practical terms, this means sustained loss of hepatitis B surface antigen (HBsAg), undetectable or very low levels of viral DNA in the blood, and normalization of liver biochemistry, ideally accompanied by seroconversion to antibodies against the surface antigen. Achieving this endpoint dramatically reduces the risk of hepatocellular carcinoma and the progression of the liver toward cirrhosis and terminal disease, which is precisely why it is regarded as the paramount objective of CHB management.

Yet the numbers remain sobering. According to the review, even with the best currently available regimens, the functional cure rate among patients with chronic hepatitis B stays below 30 percent, and in many treatment settings it is far lower. Nucleos(t)ide analogues such as entecavir and tenofovir suppress viral replication with remarkable potency and an excellent safety profile, but they act on the reverse transcriptase step of the hepatitis B virus life cycle and leave the intracellular reservoirs of viral genetic material untouched. Pegylated interferon-alpha, the other pillar of standard therapy, can reinvigorate antiviral immune responses in a subset of patients, but response rates are limited and tolerability issues frequently force discontinuation. The result is a therapeutic plateau: viral suppression is easy to achieve, but genuine immune-mediated control of the infection remains the exception rather than the rule.

At the heart of this plateau, the authors identify the persistence of covalently closed circular DNA, or cccDNA, as the central virological obstacle. cccDNA is the circular, episodic form of the hepatitis B virus genome that resides in the nucleus of infected hepatocytes and serves as the transcriptional template for all viral RNAs, including the pregenomic RNA from which new viral particles are assembled. Because cccDNA is stable, long-lived and present in minute quantities per cell, it evades both the cytoplasmic degradation pathways triggered by nucleos(t)ide analogues and the surveillance of the immune system, which struggles to recognize infected hepatocytes that produce little or no viral antigen. Clearing cccDNA from the liver would require either eliminating every infected hepatocyte or inducing selective degradation of the minichromosome itself, and neither approach is currently achievable with acceptable safety in the overwhelming majority of patients.

Compounding the cccDNA problem is a second form of viral persistence that the review highlights in detail: the integration of hepatitis B virus DNA into the genome of the host hepatocyte. Integration occurs frequently during the chronic phase of infection, driven by the_error-prone nature of viral replication and the continual turnover of infected cells. Integrated viral sequences are typically rearranged and replication-defective, but they can act as persistent factories for hepatitis B surface antigen, sustaining high circulating levels of HBsAg even when cccDNA transcription has been effectively silenced. This has two major consequences. First, integrated DNA means that surface antigen loss cannot automatically be equated with the elimination of the viral reservoir, complicating the interpretation of treatment endpoints. Second, chromosomal integration is a recognized mutagenic event, and insertional disruption of host genes such as TERT has been implicated in the development of hepatocellular carcinoma, linking viral persistence directly to the most feared clinical outcome of chronic infection.

The review then turns to the immunological face of the problem, describing how prolonged exposure to elevated levels of viral antigens — above all hepatitis B surface antigen and hepatitis B e antigen — induces a state of immune tolerance that is sculpted from the very earliest stages of infection. In patients infected at birth or in early childhood, the developing immune system encounters enormous quantities of circulating antigen during the critical windows in which tolerance mechanisms are established. High antigen loads drive the deletion or functional silencing of HBV-specific T cells, promote the differentiation of regulatory T cells and exhaust antigen-presenting dendritic cells, so that by the time chronicity is established the immune system has been trained, in effect, to ignore the virus. Maternal antigen passage and the unique tolerogenic environment of the liver, which is continuously exposed to gut-derived material and normally biased toward immune non-responsiveness, reinforce this state and help explain why infection acquired early in life so rarely resolves spontaneously.

Even in patients whose T cells do persist, the review documents a landscape of immune exhaustion and dysfunction operating at multiple regulatory levels. HBV-specific CD8 T cells in chronic hepatitis B display the classic molecular signature of exhaustion: sustained expression of inhibitory receptors such as PD-1, CTLA-4, TIM-3 and LAG-3, shortened telomeres, impaired cytotoxic function and a shift toward a terminally differentiated, senescent phenotype. CD4 helper function is similarly compromised, weakening the support that CD8 cells require for sustained antiviral activity. Beyond the T cell compartment, natural killer cell function is dysregulated, B cell responses are blunted with defective production of neutralizing anti-HBs antibodies, and the intrahepatic cytokine milieu — enriched in suppressive mediators such as interleukin-10 and indoleamine 2,3-dioxygenase — actively restrains inflammatory responses. Exhausted T cells, the authors emphasize, are not simply passive casualties; they represent a partially reversible differentiation state, which is precisely why they have become the focal point of new immunotherapeutic strategies.

It is against this mechanistic backdrop that the review surveys the emerging arsenal of immunotherapy. Therapeutic vaccines aim to present HBV antigens in an immunogenic context that can break tolerance and prime new antiviral T cell responses. Checkpoint inhibitors, most notably antibodies directed against PD-1 or PD-L1, seek to reverse the exhausted state of HBV-specific T cells, an approach supported by incidental observations of HBsAg decline in cancer patients treated with such agents. Agonists of pattern-recognition receptors, including Toll-like receptor 7 and 8 agonists, are designed to reawaken innate antiviral defenses and restore interferon production within the liver. Additional strategies under investigation include engineered T cell technologies, cytokine modulation, and combinations that pair direct-acting antivirals with immune interventions to first reduce antigen load and then rebuild antiviral immunity. The authors stress, however, that no single agent has yet demonstrated the capacity to induce functional cure reliably, and that the field’s most promising direction lies in rational combination: reducing the antigenic burden, releasing the brakes on T cell function, and providing the innate cytokine signals needed to coordinate a durable multi-layered response.

The review also underscores why the liver’s unique immunobiology makes this task so difficult. The hepatic environment is constitutively tolerogenic, populated by liver sinusoidal endothelial cells, Kupffer cells and stellate cells that favor the induction of regulatory rather than effector T cell responses. Any curative strategy must therefore overcome not only the viral reservoirs and the exhaustion of the adaptive immune system, but also an organ-specific architecture that has evolved to suppress inflammation. Biomarker development is identified as an equally pressing need: quantitative HBsAg levels, hepatitis B RNA signatures and emerging measures of immune restoration are all being explored as tools to identify which patients are most likely to benefit from which combination, and to shorten the lengthy trials that current endpoints demand.

By synthesizing virological persistence mechanisms, the layered failure of antiviral immunity and the emerging immunotherapeutic toolkit into a single framework, Lin, Yu and Sun aim to provide both a theoretical foundation and practical critical perspective for the clinical translation of functional cure strategies. Their central message is one of mechanistic realism: the obstacles to curing chronic hepatitis B functionally are not a single barrier but an interlocking system of viral reservoirs, integrated DNA, antigen-driven tolerance and multi-level immune exhaustion. Understanding how these pieces reinforce one another — and designing combinations that dismantle them in the correct sequence — is, the authors conclude, the surest path toward turning a goal achieved by fewer than a third of patients today into a routine clinical outcome tomorrow.

Subject of Research: Immunological mechanisms and barriers to achieving a functional cure for chronic hepatitis B

Article Title: The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B

Article References: Lin, L., Yu, D., & Sun, S. (2026). The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B. Virology Journal. https://doi.org/10.1186/s12985-026-03310-2

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03310-2

Keywords: chronic hepatitis B, functional cure, HBV, cccDNA, HBsAg loss, immune exhaustion, viral integration, immunotherapy, T cell dysfunction, immune tolerance, liver disease, antiviral therapy